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Sensing tissue damage is an ancient function of immune cells, that regulates inflammation, 
tissue repair and immunity. In this issue of Immunity, Ken Rock and colleagues uncover the role 
of Clec2d as a cell death receptor sensing released histones during necrosis, which contributes 






While physiological clearance of cells undergoing apoptosis is mostly immunologically silent, 
inflammation triggered after sensing of necrosis or certain forms of immunogenic apoptosis 
constitutes a warning during tissue damage events. This is related to Polly Matzinger’s danger 
theory (refined in (Matzinger, 2002)), proposing that immune cells may become activated after 
sensing molecular traits released or exposed following tissue damage, defined as Danger-
Associated Molecular Patterns (DAMPs), which would be otherwise sheltered intracellularly. In 
this line, macrophages and dendritic cells (DCs) are early damage sensors, as they are present 
in virtually any tissue, and are equipped with DAMP-sensing receptors. Activation of 
macrophages and DCs ignites the recruitment of other immune cells and the production of 
cytokines that contribute to inflammation and immunity, which can help to contain the insult and 
initiate tissue repair processes. However, production of proinflammatory cytokines, reactive 
oxygen species and some other immune effector mechanisms can cause undesired 
immunopathological damage to the host tissue. Therefore, it is fundamental to understand the 
mechanisms involved in the fine-tuning of the balance between the protective and detrimental 
effect of immune responses following sensing of tissue damage by myeloid cells. Ken Rock and 
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colleagues (Lai et al., 2019) seeked for new cell death receptors expressed in macrophages. 
They focused their attention in C-type lectin receptors (CLRs) as a versatile group with a C-type 
lectin domain that binds many endogenous ligands, and acting as DAMP sensors such as 
DNGR-1/Clec9a and MINCLE/Clec4e. 
 The authors generated T cell lines expressing the hemagglutinin (HA)-tagged 
ectodomain of the investigated CLRs fused to the CD3ζ intracellular domain and coupled to an 
NFAT/luciferase-based reporter {Sancho, 2009}. When these chimeric receptors are triggered 
either by binding their ligands or crosslinking with specific antibodies against the CLR or the HA 
epitope, luciferase is expressed, thus acting as a reporter for specific CLR binding. To test 
necrosis-derived ligands with these reporter cell lines bearing different CLR-CD3ζ chimeras, the 
authors treated mouse and human cell lines and primary mouse splenocytes either with UV-
irradiation, freeze and thaw cycles or heat-shock, followed by 8 hours of incubation with the 
reporter cell line. Both supernatant from necrotic cultures and paraformaldehyde-fixed necrotic 
cells activated Clec2d-expressing reporter cells (but not Clec1b- or Clec4a2-expressing), while 
live cells did not. Using an alternative approach, ligands were FACS-stained on the surface of 
necrotic but not on live cells by Clec2d ectodomain fused to mouse IgG Fc. These data 
indicated that Clec2d was able to recognize ligand/s exposed and released by necrotic cells and 
evolutionarily conserved in mouse and human. 
The authors next deciphered the biochemical nature of this ligand, showing that it was 
sensitive to proteases, but rather resistant to SDS-denaturation, suggestive of a primary 
polypeptide sequence. Taking advantage of this, the authors tested SDS-PAGE fractions in the 
cell reporter assay followed by mass spectrometry of those fractions that triggered the reporter 
assay, containing the Clec2d ligand/s. This clever approach led to the identification of histones 
as the Clec2d ligand. The activation of the Clec2d-expressing reporter cell line by thymus-
purified and recombinant histones, and complementary pull-down experiments using histone-
coated beads with soluble Clec2d confirmed that all five histones (H1, H2A/B, H3, H4) are 
ligands for Clec2d. This is a very relevant finding, as histones were already known DAMPs (Silk 
et al., 2017), but whether there was a dedicated receptor for them was not clear. A detailed 
mapping uncovered that, rather than a particular aminoacid sequence, a poly-basic motif found 
in all the histones was essential for binding to Clec2d. The alteration of this basic nature (either 
by mutation or acetylation) impaired the Clec2d binding capacity of histones. 
Clec2d was early shown to bind sulfated glycosaminoglycans in a calcium-independent 
manner (Gange et al., 2004). Interestingly, histones can bind sulfated polysaccharides through 
their basic N-terminus region (Watson et al., 1999), the same that Lai et al. show now as critical 
for binding Clec2d (Lai et al., 2019). Taking all together, it is tempting to speculate that the 
binding of Clec2d to histones in vivo occurs via sulfated glycans bound to histones. In this 
sense, it would be interesting to know whether Clec2d activation by purified histones is sensitive 
to heparinase treatment.  
 To investigate the potential physiological relevance of Clec2d sensing of histones, the 
authors used a well-established model of hepatic injury by mouse exposure to an overdose of 
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acetaminophen/paracetamol (APAP), where histones are released systemically as a 
consequence of liver damage (Xu et al., 2011). Of note, serum from APAP-treated mice induced 
the activation of the Clec2d-expressing reporter cell, correlating with high serum levels of the 
hepatic enzyme alanine aminotransferase (ALT) as a readout of liver injury. To demonstrate 
that histones are the DAMPs recognized by Clec2d in this model, purified histones from the 
serum of APAP-treated mice activated the Clec2d-expressing reporter cell line, and this 
activation was abolished when histones were immunodepleted from the serum. The authors 
next addressed what are the pathophysiological consequences of sensing histones by Clec2d in 
this tissue damage model. Clec2d-deficient mice were protected during APAP-induced liver 
injury, showing reduced serum ALT levels and better survival. To connect this phenotype with 
histone recognition, intravenous administration of purified histones induced the production of 
serum proinflammatory cytokines in WT mice, which was reduced in Clec2d-deficient settings. 
All these evidences support the notion that Clec2d-sensing of histones released upon tissue 
injury in this model mediates cytokine-driven inflammation, leading to further late liver damage, 
although a direct demonstration is missing. 
Exposure of Clec2d expressing macrophages to purified histones did not result in 
inflammatory cytokine production, suggesting that Clec2d is not a signaling receptor per se. The 
authors reasoned that histones are released as complexes with DNA that could be sensed 
intracellularly by endosomal TLR9. As they showed that Clec2d is expressed in macrophages at 
the surface but also in endo-phagosomes, they hypothesized that Clec2d could be trafficking 
histone-DNA complexes to endosomes to initiate TLR9-mediated inflammatory responses. After 
checking that the TLR9 ligand CpG binds to histones but does not activate Clec2d by itself, they 
showed that CpG and histone co-stimulation boosts the inflammatory response in WT 
macrophages. This synergistic response was dampened in Clec2d-deficient cells while Tlr9-
deficient macrophages do not respond at all. The Clec2d-dependent synergistic effect on the 
inflammatory capacity of DNA was confirmed when using whole nucleosomes (complexes of 
histones and DNA) and again, this response was DNA-dependent, as DNAse I treatment killed 
cytokine production in response to nucleosomes. Finally, co-existence of DNA and Clec2d 
ligands was also shown in Neutrophil Extracellular Traps (NETs) after neutrophil activation. This 
is reminiscent of the role of High Mobility Group B (HMGB) proteins in binding immunogenic 
nucleic acids facilitating sensing by endosomal TLRs (Yanai et al., 2009). Since HMGB1 has 
polybasic regions, this opens the additional possibility that Clec2d may bind HMGB1 in an SDS-
sensitive manner, and contribute to some of its effects. 
 The take-home message from this work is that Clec2d recognizes histones released 
during tissue damage and those histones are coupled to DNA; Clec2d carries the histone-DNA 
complexes to endosomal compartments where DNA can be sensed by TLR9, leading to 
inflammatory cytokine production (Figure 1). This damage-sensing pathway contributes to 
further inflammation and collateral tissue damage. 
The precise Clec2d-dependent factors accounting for this secondary tissue injury are 
unexplored in this work. Direct inflammatory responses triggered in resident macrophages could 
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contribute to that tissue damage. Neutrophils and monocytes are recruited to the liver upon 
APAP treatment (Krenkel et al., 2014), with potential to mediate immunopathology. However, 
the relationship between Clec2d and Natural Killer (NK) cells deserves some attention. 
NKRP1d, an inhibitory NK cell-associated receptor was identified as a Clec2d ligand and 
therefore, NKRP1d dampens NK-mediated cytotoxicity when bound to Clec2d (Iizuka et al., 
2003). Considering the discussed role of NK cells in the APAP-induced liver damage model 
(Krenkel et al., 2014), it would be interesting to elucidate the role of Clec2d in NK-mediated 
cytotoxicity, especially to translate this knowledge to other fields such as cancer 
immunotherapy. 
In the original characterization of Clec2d-deficient mice generated by the lab of Dr. 
Gillespie, they described that 10 to 16 weeks-old mice show an osteopenic phenotype 
(Kartsogiannis et al., 2008). This is primarily due to the osteoblast-derived inhibitor role of 
Clec2d over osteoclast formation (Zhou et al., 2002), accounting for the OsteoClast Inhibitory 
Lectin (OCIL) nomenclature for Clec2d. In that seminal work, they reported “no apparent 
immune function defect” of Clec2d-deficient mice, as the loss of the receptor did not impact on 
the cellularity of immune populations nor the expression of activation markers in the steady-
state (Kartsogiannis et al., 2008). Interestingly, mice used by Lai et al. were from the same 
source, which were further backcrossed to C57BL/6J for this work. For the APAP-induced liver 
injury experiments, 10 to 14 weeks old mice were used, which might be beginning to show bone 
alterations. It could be speculated that this fact could impact the immune phenotype upon 
experimental tissue damage conditions. Therefore, performing these studies in young mice 
would merit further studies. 
 In summary, this work places Clec2d as a new death cell receptor sensing histones as 
DAMPs. This bears important clinical implications as it would allow the targeting of just a single 
receptor instead of diverse histones in order to reduce immunopathology in certain tissue 
damage-causing pathologies. In addition, sensing histones from solid tumors with massive 
necrosis through Clec2d could be exploited to favor a pro-inflammatory anti-tumor response. In 
fact, tumor cells can show reduced global levels of histone modification, which may favor 
Clec2d sensing. This work thus opens a fascinating avenue of research in order to 






Figure 1. Histones recognition by Clec2d contributes to immunopathology upon tissue 
damage conditions. Overdose administration of APAP (acetaminophen / paracetamol) triggers 
necrosis of hepatocytes, with a subsequent release of the intracellular content, such as 
nucleosomes containing histone-DNA complexes. Clec2d, expressed on the surface of 
macrophages, recognizes poly-basic motifs on histones, trafficking histone-DNA complexes into 
endosomal compartments. Endosomal TLR9 can then gain access to immunostimulatory DNA, 
triggering the expression of proinflammatory cytokines such as TNF, IL-6, IP-10 and RANTES. 
This inflammatory response further contributes to liver injury by unaddressed mechanisms that 
may include direct collateral damage by the inflammatory cytokines or further recruitment of 
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